Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X, Zhu L, Ma Z, Sun G, Luo X, Li M, Zhai S, Li P, Wang X.
Chen X, et al. Among authors: li m, li p.
Sci Rep. 2015 Nov 23;5:17031. doi: 10.1038/srep17031.
Sci Rep. 2015.
PMID: 26593208
Free PMC article.